Castle Biosciences
CSTL
Castle Biosciences (CSTL) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.07
- EPS estimate
- −$0.41
- EPS surprise
- +82.81%
- Revenue surprise
- +20.07%
- Revenue
- $103.5M
- Revenue estimate
- $86.2M
- Reported
- Jul 30, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 30, 2026 | −$0.41 | −$0.07 | +82.81% | $103.5M | SEC |
| Q1 2026 | May 6, 2026 | −$0.49 | −$0.49 | +0.00% | $84.2M | SEC |
| Q4 2025 | Feb 26, 2026 | −$0.26 | −$0.08 | +69.06% | $87.0M | SEC |
| Q3 2025 | Nov 3, 2025 | −$0.52 | −$0.02 | +96.16% | $83.0M | SEC |
| Q2 2025 | Aug 4, 2025 | −$0.53 | $0.15 | +128.24% | $86.2M | SEC |
| Q1 2025 | May 5, 2025 | −$0.07 | −$0.90 | −1196.83% | $87.2M | SEC |
| Q4 2024 | Feb 27, 2025 | $0.05 | $0.32 | +579.41% | $85.8M | SEC |
| Q3 2024 | Nov 4, 2024 | −$0.00 | $0.08 | +2100.00% | $85.8M | SEC |
| Q2 2024 | Aug 5, 2024 | −$0.27 | $0.31 | +215.37% | $86.6M | SEC |
| Q1 2024 | May 2, 2024 | −$0.33 | −$0.09 | +72.89% | $71.3M | SEC |
| Q4 2023 | Feb 28, 2024 | −$0.56 | −$0.10 | +82.22% | $66.1M | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.76 | −$0.26 | +65.97% | $60.6M | SEC |
| Q2 2023 | Aug 2, 2023 | −$0.92 | −$0.70 | +23.51% | $50.2M | SEC |
| Q1 2023 | May 3, 2023 | −$0.89 | −$1.10 | −23.53% | $43.4M | SEC |
| Q4 2022 | Feb 28, 2023 | −$0.84 | −$0.78 | +6.88% | $38.3M | SEC |
| Q3 2022 | Nov 2, 2022 | −$0.88 | −$0.77 | +12.56% | $37.0M | SEC |
| Q2 2022 | Aug 8, 2022 | −$0.76 | −$0.06 | +92.12% | $34.8M | SEC |
| Q1 2022 | May 9, 2022 | −$0.71 | −$0.97 | −37.18% | $26.9M | SEC |
| Q4 2021 | Feb 28, 2022 | −$0.47 | −$0.25 | +46.87% | $25.0M | SEC |
| Q3 2021 | Nov 8, 2021 | −$0.41 | −$0.47 | −16.05% | $23.5M | SEC |
Quarterly revenue
Frequently asked questions
When did Castle Biosciences (CSTL) last report earnings?
Castle Biosciences last reported on Jul 30, 2026, covering fiscal Q2 2026.
Did CSTL beat earnings estimates?
Yes. Castle Biosciences reported EPS of −$0.07 for Q2 2026 against a −$0.41 estimate — a 82.81% beat.
How much revenue did CSTL report last quarter?
Castle Biosciences reported $103.5M in revenue for Q2 2026, against a consensus estimate of $86.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.